SI-BONE (SIBN) Scheduled to Post Quarterly Earnings on Monday

SI-BONE (NASDAQ:SIBN) is scheduled to issue its quarterly earnings data after the market closes on Monday, May 6th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

SI-BONE (NASDAQ:SIBN) last issued its earnings results on Monday, February 26th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.02. The business had revenue of $38.86 million during the quarter, compared to analyst estimates of $38.60 million. SI-BONE had a negative return on equity of 28.22% and a negative net margin of 31.20%. On average, analysts expect SI-BONE to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

SI-BONE Trading Up 2.1 %

NASDAQ SIBN opened at $14.57 on Monday. The company has a quick ratio of 8.15, a current ratio of 9.01 and a debt-to-equity ratio of 0.21. SI-BONE has a 52 week low of $14.12 and a 52 week high of $29.51. The business has a 50 day moving average price of $16.60 and a 200-day moving average price of $18.14. The company has a market cap of $598.24 million, a price-to-earnings ratio of -12.78 and a beta of 1.20.

Insider Buying and Selling at SI-BONE

In related news, Director Mika Nishimura sold 2,500 shares of the stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $16.22, for a total transaction of $40,550.00. Following the transaction, the director now owns 19,350 shares of the company’s stock, valued at approximately $313,857. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other SI-BONE news, Director Mika Nishimura sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $16.22, for a total value of $40,550.00. Following the completion of the sale, the director now owns 19,350 shares in the company, valued at $313,857. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Anthony J. Recupero sold 3,307 shares of the stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $15.50, for a total transaction of $51,258.50. Following the sale, the insider now directly owns 252,453 shares of the company’s stock, valued at approximately $3,913,021.50. The disclosure for this sale can be found here. Insiders have sold 11,562 shares of company stock worth $185,285 over the last 90 days. Corporate insiders own 5.40% of the company’s stock.

Analyst Upgrades and Downgrades

SIBN has been the topic of several recent analyst reports. Truist Financial restated a “buy” rating and set a $24.00 price objective (down from $26.00) on shares of SI-BONE in a research note on Tuesday, February 27th. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price target on shares of SI-BONE in a research report on Tuesday, February 27th. Piper Sandler began coverage on shares of SI-BONE in a research report on Thursday, March 28th. They issued an “overweight” rating and a $25.00 price objective for the company. Morgan Stanley lifted their target price on shares of SI-BONE from $25.00 to $26.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $27.00 price target on shares of SI-BONE in a research report on Wednesday, April 3rd. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, SI-BONE has a consensus rating of “Buy” and an average target price of $26.67.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.